

The poster session will be between 4-6 pm on Wednesday, June 25th in the Arizona Grand Ballroom - Eucalyptus and Honeysuckle Suites. The presenting author is expected to be at their poster as follows: those with odd numbered abstracts should stand by their posters for the first hour and those with even numbered abstracts will stand by their poster for the second hour. Posters should remain in situ until the afternoon session on Thursday, June 26th to allow for viewing during breaks and lunches. You do not need to be at the poster boards during this time. Please remove your poster at the end of the afternoon break on day 2.

Category	Presenting Author	Abstract Title	#
Advances in Clinical Care Across the Lifespan			
ACC	Bohonwych, J	The Global Schaaf-Yang syndrome (SYS) Registry: Launch and Early Demographics.	1
ACC	Cassidy, J	Behavioral, Activity, and Physiological Outcomes in Pediatric Prader-Willi Syndrome: A Comprehensive Analysis.	2
ACC	Cheng, T	Fatalities due to Pulmonary Embolism in Prader-Willi Syndrome: Case Studies.	3
ACC	Diene, G	The French Prader-Willi Registry: An Essential Tool for Clinic and Research on Prader-Willi Syndrome.	4
ACC	Faucher, P	Therapeutic education: a way to support adults living with Prader Willi syndrome and their caregivers to improve their care pathway.	5
ACC	Gevers, E	A resource for practical food portions for children and adults with Prader-Willi syndrome.	6
ACC	Hoffman, D	Comorbidity Burden of Prader-Willi Syndrome Among Pediatric Patients in the United States.	7
ACC	Hoffman, D	The Burden of Anxiousness and Distress Behaviors in Prader-Willi Syndrome.	8
ACC	Johansson, A	Development of Anticipatory Guidance Materials for Families Attending an Interdisciplinary Prader-Willi Syndrome Clinic: A Quality Improvement Project.	9
ACC	Oto, Y	Age Differences and Support Needs in Adults with Prader-Willi Syndrome: Insights from FIM Analysis.	10
ACC	Pacha, D	Evaluating Current Educational Trends of Children with PWS in the United States -A Survey Study.	11
ACC	Paprocki, E	International Survey of Clinicians' Perspectives Toward Growth Hormone Therapy and Sleep Evaluation in Infants with Prader-Willi Syndrome.	12
ACC	Rubin, D	Biomechanical and Neuromuscular factors in a daily motor task in Prader-Willi syndrome.	13
ACC	Scheimann, A	Long-Term Outcomes of Prader-Willi Syndrome Association USA Funding Awards.	14
ACC	Stegmann, J	Innovative Virtual Plan for Comprehensive Clinical Management of Individuals with Prader-Willi Syndrome.	15
ACC	Strong, T	Research Resources for the PWS & SYS Clinical and Scientific Community.	16
ACC	Weaver, K	A Scoping Review of Pediatric to Adult Healthcare Transition Research for Youth with Prader-Willi Syndrome.	17
ACC	Webster, D	The Australian PWS Research Roadmap.	18

Category	Presenting Author	Abstract Title	#
Advances in Endocrinology			
AE	Angulo, M	Aromatase Inhibitor (Anastrozole) Improves Near Adult Height (AH) in Growth Hormone Treated Adolescents with Prader-Willi Syndrome.	19
AE	Diene, G	Circulating levels of ghrelin in patients with a rare neurodevelopmental disorder associated with hyperphagia, and/or overweight, and/or obesity - The HOGGRID study.	20
AE	Goos, J	The Dutch experience with weight-loss drugs in adults with Prader-Willi syndrome.	21
AE	Roy, S	Avascular Necrosis and Pseudotumor Cerebri in a Child with Prader-Willi syndrome on Growth Hormone Therapy.	22
AE	Yordonova, N	The impact of adipo(myo)kines on metabolic profile of PWS patients followed at a Single Expert Center of Rare Endocrine Diseases.	23
Cellular and Molecular			
CM	Bayat, T	Reprogramming of mRNA Translation upon Loss of Magel2 in the Mouse Hypothalamus and Pituitary.	24
CM	Carrasco-Garcia, A	Role of mitochondrial function in the oxidative stress profile of children with Prader-Willi syndrome.	25
CM	Good, D	Unique spatial expression patterns in response to Snord116 and energy availability define mechanisms for post transcriptional regulation of Nhlh2: Implications for Prader-Willi syndrome.	26
CM	Hedgecock, T	Modulating circadian rhythm dysregulations in PWS neurons and U2OS cells using pharmacological agents.	27
CM	Helwark, A	The role of SNORD115 and SNORD116 in neuronal development.	28
CM	Qureshi, Y	Dysregulation of Secretory Pathways and Retromer Function in Prader-Willi syndrome Type 1: Insights from Mouse Models and Induced Neurons.	29
CM	Singh, R	Mining Biological Networks at Scale: A Path to New Therapeutic Targets in Prader-Willi Syndrome.	30
CM	Smith, J	The Heart of SNORD116: Investigating the Role of SNORD116 in Cardiomyocyte Development.	31
CM	Tacer, K	Novel Insights into the Function of MAGEL2 in Fed and Fasted States.	32
CM	Zou,C	Effect and mechanism of SNORD116 deficiency mediated mitochondrial dysfunction in neural differentiation disorders of PWS.	33
Clinical Trials			
CT	Cowan, N	Swallowability and Dosing Compliance of Diazoxide Choline Extended-Release Tablets in Patients with Prader-Willi Syndrome.	34
CT	Ferretti, C	Cannabidiol (CBDV) vs. Placebo for Rigid and Repetitive Behaviors in Prader-Willi Syndrome (PWS).	35
CT	Ferretti, C	Intranasal oxytocin vs. placebo in children and adolescents with Prader-Willi syndrome (PWS).	36
CT	Gevers, E	Diazoxide Choline Extended-Release (DCCR) Tablets Significantly Reduce Hyperphagia in Patients with PWS who are Managed with Strict Food Controls.	37
CT	Girba, M	Can pulsatile GnRH therapy improve cognitive, behavioral and metabolic outcomes in adolescents with Prader-Willi syndrome?	38

Category	Presenting Author	Abstract Title	#
CT	Huang, M	Relaxation of Food Control Parameters Based on Improvements in the Food Safe Zone Questionnaire Occurs with Reduction of Hyperphagia in Clinical Trials of Diazoxide Choline Extended Release (DCCR) in Participants with Prader-Willi Syndrome.	39
CT	Jaiman, M	Reduction in Hyperphagia in ARD-101 Phase 2 Clinical Trial Informs Phase 3 HERO Trial in PWS.	40
CT	Liu, S	A phase 1, single center, open-label, single-dose, pharmacokinetic and safety study of CSTI-500 in subjects with Prader-Willi syndrome.	41
CT	Matesevac, L	The VNS4PWS Study: A Patient-Centric Device Trial to Reduce Temper Outbursts in Prader-Willi Syndrome (PWS).	42
CT	Miller, J	Comparison of Changes in Fat Mass in Participants with PWS Treated with DCCR to Those in the NIH Natural History Study.	43
CT	Miller, J	Safety and Efficacy of DCCR in Patients with Prader-Willi Syndrome who have Pre-Diabetes or Diabetes.	44
CT	Nahon, C	A new attractive treatment for Improving Emotion Regulation, Executive Functions, Hyperphagia, and Quality of Life in Prader-Willi Syndrome: The Auricular Vagal Neuromodulation Therapy.	45
CT	Stogren, C	The Effects of a Caregiver-Implemented Toilet Training Package Provided via Telehealth for Children with Prader-Willi Syndrome.	46
CT	Trueba-Timmermans, D	N-acetylcysteine treatment for skin-picking in children and young adults with PWS: A randomized placebo-controlled cross-over trial.	47
Gastrointestinal Issues and Nutrition			
GN	Ceccomancini, R	Impact of Genetic Subtypes on the Weight of Individuals with Prader-Willi syndrome Undergoing Outpatient Transdisciplinary Care.	48
GN	Ceccomancini, R	Long-Term Impact of Regular Transdisciplinary Care on Body Mass Index in Individuals with Prader-Willi Syndrome.	49
GN	Ceccomancini, R	Relationship Between Anthropometric Features and Genetic Subtypes in Prader-Willi Syndrome	50
GN	Gross-Tsur, V	Use of enteral feeding in Prader-Willi syndrome: 10-year experience of a national referral center.	51
GN	Guillon, E	Eating behavior and hyperphagia in adults with obesity and neurodevelopmental disorders: Insights from Prader-Willi, Bardet-Biedl and other genetic syndromes.	52
GN	Zou, C	Association among food responsiveness, food addition and hyperphagia in PWS: a cross-sectional analysis of 210 patients in China.	53
Genetics and Epigenetics			
GE	Gevers, E	Age at diagnosis in PWS.	54
GE	Johnson, L	Translational control of a unique bicistronic gene linked to Prader-Willi syndrome	55
GE	Kerkhof, G	Genome-wide changes in DNA methylation in patients with Prader-Willi syndrome	56
GE	Rodriguez, T	Single Cell Profiling Reveals Significant Differences in Transcript Expression in Dental Pulp Stem Cell Derived Prader-Willi Syndrome Neuronal Cultures.	57
GE	Schubert, T	A new computational toolkit and severity score yield deep genotype-phenotype insights in Schaaf-Yang syndrome.	58

Category	Presenting Author	Abstract Title	#
GE	Vrana-Diaz, C	Study Design and Ethical Return of Results for a Fully Remote Genome Sequencing Study in Individuals with Prader-Willi Syndrome.	59
GE	Zou, C	Glucose-6-phosphate dehydrogenase deficiency in patients with PWS.	60
Medical			
M	Davidse, K	Hypercapnia is common in lean and obese adults with Prader Willi syndrome.	61
M	Stegmann, J	Assessing Osteoarticular Challenges in Prader-Willi Syndrome: Insights into Postural Stability, Spinal Deformities, and Functional Mobility.	62
M	Suco, S	Respiratory and sleep disorders in children with Prader Willi syndrome: prevalence and characterization.	63
M	Tsai, L	The Impact of Growth Hormone Therapy on Polysomnography in Prader-Willi Syndrome Children Below 2 Years of Age.	64
M	Wilcox, A	Feasibility of Actigraphy to Measure Energy Expenditure in Children with Prader Willi Syndrome.	65
Neuroscience, Cognition, Mental Health and Behavior			
N	Bedard, K	PWS-Smart Start – Replication in a Randomized Control Trial.	66
N	Bouret, S	Vesicle-mediated Oxytocin Release Promotes the Development of Melanocortin Circuits during a Neonatal Critical Period.	67
N	Cornillon, A	Magel2-null mice Demonstrate Contradictory Behaviors in Body Weight, Impulsivity, and Motivation during Distinct Fasted States.	68
N	Dix, C	The Effects of a Caregiver-Mediated Evidence-Based Intervention On Repetitive Verbal Behavior in PWS.	69
N	Dougherty, L	The Emotional Impact of Hyperphagia: Insights from the Prader-Willi Syndrome Community.	70
N	Fangman, E	Developmental Milestones and Neonatal Metrics in PWS Population.	71
N	Forster, J	Post-COVID Encephalopathy in Adolescents and Young Adults with Prader-Willi Syndrome.	72
N	Franke, F	In-depth behavioral characterization of a rat model of Schaaf-Yang syndrome.	73
N	Galiana, A	Defining Thresholds for the Prader-Willi Syndrome Anxiety and Distress Questionnaire in Outpatient Transdisciplinary Care.	74
N	Galiana, A	Exploring Potential Predisposing and Triggering Factors for Skin Picking in Individuals with Prader-Willi Syndrome.	75
N	Galiana, A	Impact of Valproic Acid and Risperidone on Body Mass Index in Prader-Willi Syndrome: a Case Series in Outpatient Transdisciplinary Care.	76
N	Gross-Tsur, V	High Prevalence of Childhood Apraxia of Speech in Children with Prader-Willi Syndrome.	77
N	Hall, S	Functional Near-Infrared Spectroscopy of Skin Picking Behavior in Prader-Willi Syndrome.	78
N	Hasan, W	Sleep-wake dysregulation in Snord116del mice.	79
N	Kerkhof, G	Intensive family centered treatment in patients with Prader-Willi syndrome: focus on non-violent resistance training – A Pilot Study.	80

Category	Presenting Author	Abstract Title	#
N	Kimonis, V	Influence of Molecular Genetic Classes on Behavior in Prader-Willi Syndrome.	81
N	Krukowski, K	The Effects of Remote Behavioral Skills Training on Caregiver Implementation of a Play Skills Intervention to Improve Transition Behavior in Children with Prader-Willi syndrome.	82
N	Manzardo, A	Exploratory Factor Analysis and underlying factor structure of the PWS Acuity Scale in a survey sample of PWS families.	83
N	Nag, H	Psychiatric Symptoms in Prader-Willi Syndrome.	84
N	Nakane, E	The Impact of Sensory Processing and Genetic Subtypes on ABC Irritability Scores in Patients with Prader-Willi Syndrome (PWS).	85
N	Roubos, A	Sensory Information Processing, Intelligence, and Behavior in Prader-Willi Syndrome.	86
N	Shaikh, S	Feeding and Swallowing Deficits in a Prader-Willi Syndrome Mouse Model and the Treatment Effects of Oxytocin.	87
N	Stegmann, J	Assessing neuropsychological development in people with Prader-Willi syndrome.	88
N	WITHDRAWN	WITHDRAWN	89
N	Stegmann, J	Characterization of language and phonological traits in people with Prader-Willi syndrome.	90
N	Stegmann, J	Kaufman Brief Intelligence Test in Prader-Willi Syndrome: Agreement Between Virtual and In-Person Administration.	91
N	Ulm, D	Evaluating the Prevalence of Behaviors of Concern in Children with PWS – A Survey Study.	92
N	Wong, S	GABAergic Regulation of Locus Coeruleus Activity in Necdin-Deficient Mice, an Animal Model of Prader-Willi Syndrome.	93
N	Woodcock, K	Learning from people living with PWS across the world about how to best support their flourishing.	94
N	Woodcock, K	The aetiology of emotional outbursts in children and young people with Prader-Willi syndrome	95
Preclinical Developments of Novel Therapeutics			
PC	Evans, D	Profiles of Symptoms Associated with PWS Variants	96
PC	Gantz, M	Focus Groups to inform a Feasibility Pilot for use of Wearable Devices in Prader-Willi Syndrome Clinical Trials	97
PC	Gilmore, R	Investigating antisense oligonucleotides in a rat model of Schaaf-Yang syndrome.	98
PC	Welburn, P	Preclinical Findings Suggest That EPM301 Could Offer Multiple Benefits as a Novel Treatment for Symptoms of Prader-Willi syndrome.	99
PC	Zempleni, J	Delivery of genes and gene editors using programmable milk exosomes.	100

Categories

AAC - Advances in Clinical Care Across the Lifespan
 AE - Advances in Endocrinology
 CM - Cellular and Molecular
 CT - Clinical Trials
 GN - Gastrointestinal Issues and Nutrition

GE - Genetics and Epigenetics
 M - Medical
 N - Neuroscience, Cognition and Mental Health
 PC - Preclinical Developments of Novel Therapeutics